Tag «GSK 3008348»

GSK 3008348

It’s only fair to share… GSK 3008348 (3S)-3-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-4-{(3S)-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl}butanoic acid cas 1629249-33-7 1-Pyrrolidinebutanoic acid, β-[3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-, (βS,3R)- (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid (βS,3R)-β-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinebutanoic acid Molecular Formula C29H37N5O2 Average mass 487.636 Da   CAS Number: 1629249-40-6 Molecular Weight: 524.1 Molecular Formula: C29H38ClN5O2 Originator GlaxoSmithKline Mechanism of Action Integrin alphaV antagonists Phase I Idiopathic pulmonary fibrosis 06 Mar 2017 GlaxoSmithKline plans a phase I trial for Idiopathic pulmonary …